Seeking Alpha

Pharmacyclics (PCYC +8.5%) soars as positive data is released on its phase II study of the...

Pharmacyclics (PCYC +8.5%) soars as positive data is released on its phase II study of the potential blockbuster Btk inhibitor. The stock's a blockbuster itself, up nearly 60% since hitting a 52-week low in early March.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs